2. Economic studies: excluded.
Study ID | Status | Reasons for exclusion | Study type |
Davies 2007 | Excluded | Allocation: randomised. Particiapants: schizophrenia. Interventions: first vs second generation antipsychotics. Outcomes: no specific outcome measures for trifluoperazine. |
Type A |
Filippelli 2005 | Excluded | Allocation: randomised. Particiapants: schizophrenia. Interventions: atypical vs typical antipsychotics. Outcomes: no specific outcome measures for trifluoperazine. |
Type A |
Galvin 1999 | Excluded | Allocation: not randomised. | N/A |
Ghaemi 2001 | Excluded | Allocation: not randomised. | N/A |
Hanrahan 2006 | Excluded | Allocation: randomised. Particiapants: schizophrenia. Interventions: atypical vs conventional antipsychotics. Outcomes: no specific outcome measures for trifluoperazine. |
Type A |
Knapp 2008 | Excluded | Allocation: randomised. Particiapants: schizophrenia. Interventions: olanzapine vs other antipsychotics. Outcomes: no specific outcome measures for trifluoperazine. |
Type A |
Lewis 1998 | Excluded | Allocation: randomised (systematic review). | N/A |
Lewis 2006 | Excluded | Allocation: randomised (systematic review). | N/A |
Martin 2006 | Excluded | Allocation: randomised (systematic review). | N/A |
Mould 2009 | Excluded | Allocation: randomised. Particiapants: schizophrenia. Interventions: cost and effectiveness of ziprasidone, olanzapine, risperidone, haloperidol and clozapine (not trifluoperazine). |
Type A |
Stargardt 2008 | Excluded | Allocation: not randomised. | N/A |
Suttajit 2009 | Excluded | Allocation: randomised (systematic review). | N/A |